MiR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation of YBX1.

IF 1.5 4区医学 Q3 HEMATOLOGY

Turkish Journal of Hematology Pub Date : 2025-02-24 DOI:10.4274/tjh.galenos.2025.2024.0424

Huichao Wu, Lin Zhao, Huanyu Guo, Yingjie Xie, Jianhua Hu, Xinxia Tan

{"title":"MiR-379-5p Inhibited the Proliferation of Acute Myeloid Leukemia Cells Through Negative Regulation of YBX1.","authors":"Huichao Wu, Lin Zhao, Huanyu Guo, Yingjie Xie, Jianhua Hu, Xinxia Tan","doi":"10.4274/tjh.galenos.2025.2024.0424","DOIUrl":null,"url":null,"abstract":"Objectives: Acute myeloid leukemia (AML) is a frequent and highly lethal hematological malignancy that is difficult to treat. The research aimed to clarify the molecular mechanisms of MIR-379-5p in AML progression.Materials and methods: RT-qPCR was utilized to evaluate MIR-379-5p expression levels in AML patients and a control group. A ROC curve was created to assess the clinical predictive value of MIR-379-5p in AML, while cell experiments used CCK-8 assay, flow cytometry, and Transwell chambers. Predicted potential target genes of MIR-379-5p by employing online bioinformatics tools, followed by validation using a dual luciferase reporter assay.Results: MIR-379-5p was significantly decreased in AML patients and had clinical predictive value for the disease. In AML cell lines, MIR-379-5p was down-regulated; conversely, the up-regulation of MIR-379-5p inhibited proliferation, migration, and invasion while promoting apoptosis. Notably, YBX1 was a potential target gene of MIR-379-5p, and its upregulation reduced the effects of MIR-379-5p on AML cell behavior.Conclusion: MIR-379-5p had the potential as a biomarker for AML by regulating cell proliferation and apoptosis through targeting YBX1.","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2025.2024.0424","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Acute myeloid leukemia (AML) is a frequent and highly lethal hematological malignancy that is difficult to treat. The research aimed to clarify the molecular mechanisms of MIR-379-5p in AML progression.

Materials and methods: RT-qPCR was utilized to evaluate MIR-379-5p expression levels in AML patients and a control group. A ROC curve was created to assess the clinical predictive value of MIR-379-5p in AML, while cell experiments used CCK-8 assay, flow cytometry, and Transwell chambers. Predicted potential target genes of MIR-379-5p by employing online bioinformatics tools, followed by validation using a dual luciferase reporter assay.

Results: MIR-379-5p was significantly decreased in AML patients and had clinical predictive value for the disease. In AML cell lines, MIR-379-5p was down-regulated; conversely, the up-regulation of MIR-379-5p inhibited proliferation, migration, and invasion while promoting apoptosis. Notably, YBX1 was a potential target gene of MIR-379-5p, and its upregulation reduced the effects of MIR-379-5p on AML cell behavior.

Conclusion: MIR-379-5p had the potential as a biomarker for AML by regulating cell proliferation and apoptosis through targeting YBX1.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.